GILDHealthcare · Drug Manufacturers - GeneralThe 28 Wall Street analysts covering Gilead Sciences, Inc. hold a median 12-month price target of $165 — +3.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Gilead Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Issuance (51): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GILD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.6% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | B of A Securities | Maintains | Buy | $168 → $172 |
| 8 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 8 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 8 Oct 2026 | RBC Capital | Maintains | Sector Perform | — |
| 8 Oct 2026 | RBC Capital | Maintains | Sector Perform | $123 → $126 |
| 7 Oct 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Oct 2026 | JP Morgan | Maintains | Overweight | $160 → $170 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | — |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | $165 → $163 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | — |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $150 → $158 |
| 10 Sept 2026 | HSBC | Maintains | Buy | $155 → $175 |
| 10 Sept 2026 | HSBC | Maintains | Buy | — |
| 5 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 5 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 5 Aug 2026 | Needham | Reiterates | Buy | $170 |
| 5 Aug 2026 | Needham | Reiterates | Buy | — |
| 5 Aug 2026 | RBC Capital | Maintains | Sector Perform | $120 → $123 |
| 5 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 29 July 2026 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GILD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Gilead Sciences, Inc. returned +38.3% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 41% of US stocks
Cheaper than 19% of US stocks
Cheaper than 6% of US stocks
Cheaper than 23% of US stocks
Higher than 53% of US stocks
Higher than 49% of US stocks
Higher than 90% of US stocks
Higher than 89% of US stocks
Higher than 19% of US stocks
Higher than 31% of US stocks
Higher than 96% of US stocks
Higher than 80% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Gilead Sciences, Inc. has a market value of $197.3B and an enterprise value of $218.5B.
Revenue in the twelve months to 30 June 2026: $30.5B. The latest quarter grew 10.2% year on year.
Net income over the same four quarters: −$3.2B, a −10.6% net margin.
Diluted earnings per share, trailing twelve months: $−2.67.
Free cash flow in the twelve months to 30 June 2026: $12.9B.
Gilead Sciences, Inc. spent $1.4B on share buybacks and $4.1B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 17.9×; forward P/E: 16.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.06%, paying out 43% of earnings.
Gilead Sciences, Inc. employs 17,000 people — $1.8M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Gilead Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A 24/7 Wall Street article highlights upcoming earnings reports from Eli Lilly, Merck and Gilead, noting that Gilead is burning through cash fast.
Why it matters — The article's concern about Gilead's cash use is relevant to investors following the company's financial position.
Ahead of its Q3 earnings report, Gilead is described as having strong HIV sales, Yeztugo momentum and expanding oncology prospects, alongside competitive pressures.
Why it matters — GILD watchers may weigh these growth drivers against competition as the company approaches its earnings report.
Zacks Investment Research noted that Gilead Sciences and four other drug and biotech companies are preparing to report Q3'26 results.
Why it matters — GILD watchers may follow the upcoming quarterly report as part of the biotech earnings season.
Zacks Investment Research previews Gilead’s Q3 earnings, directing attention beyond revenue and earnings estimates to key metrics for the quarter ended September 2026.
Why it matters — The article highlights operating metrics that GILD watchers may review for additional context on the quarter’s performance.
The Motley Fool compares Amgen and Gilead as dividend stocks, noting that both have forward yields above 2%. Gilead has a lower dividend payout ratio, while Amgen is generating stronger sales growth.
Why it matters — The comparison highlights Gilead’s payout ratio alongside Amgen’s stronger sales growth for investors tracking GILD’s dividend and business performance.
The 28 Wall Street analysts covering Gilead Sciences, Inc. have a median 12-month price target of $165, with estimates ranging from $126 to $185. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Gilead Sciences, Inc., 22 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gilead Sciences, Inc. 98 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Gilead Sciences, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +3.6% from the last close, and Ticker Nerd's factor model ranks Gilead Sciences, Inc. 98 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Gilead Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GILD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $126 to $185 over the next 12 months.
Gilead Sciences, Inc. returned +38.3% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases.
The most recent item we track (24/7 Wall Street, 28 Oct 2026): "3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead". A 24/7 Wall Street article highlights upcoming earnings reports from Eli Lilly, Merck and Gilead, noting that Gilead is burning through cash fast.
Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly strong position in HIV treatment and a broader portfolio that also addresses liver disease, respiratory conditions, cardiovascular disease, and cancer. Gilead Sciences Inc. markets established therapies and newer medicines aimed at unmet medical needs, supported by ongoing research and clinical programs across multiple therapeutic areas. The company also works with partnerships and access programs that help expand the reach of its medicines in global markets. Headquartered in Foster City, California, Gilead Sciences Inc. operates as an important healthcare innovator with products and services that serve patients, clinicians, and health systems worldwide.
CEO Mr. Daniel Patrick O'Day · 17,000 employees · United States · https://www.gilead.com
